ADAR1 regulates melanoma cell invasiveness by controlling beta3-integrin via microRNA-30 family members.
ITGB3
Melanoma
RNA editing
integrin
invasion
metastasis
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
05
2020
accepted:
07
07
2020
entrez:
9
9
2020
pubmed:
10
9
2020
medline:
10
9
2020
Statut:
epublish
Résumé
Melanoma cells utilize multiple mechanisms to exit the primary tumor mass, invade the surroundings and subsequently distant tissues. We have previously reported that the expression of the RNA editing enzyme ADAR1 (adenosine deaminase acting on RNA) is downregulated in metastatic melanoma, which facilitates proliferation and invasion. Here we show that ADAR1 controls melanoma invasiveness by regulating ITGB3 expression via miR-30a and miR-30d. ADAR1 overexpression or knockdown leads to an increase or decrease, respectively, in the expression of both microRNAs. The effect is independent of RNA-editing. Dual luciferase assays show that both microRNAs directly regulate the expression of the ITGB3 integrin. Overexpression of the miR-30a or miR-30d lead to a decrease in ITGB3 and a resultant decreased invasive and metastatic capacities. Neutralization of the endogenous miR-30a or miR-30d leads to the opposite effect. The microRNAs regulate ITGB3 levels probably through a post-transcriptional effect, as both mRNA and protein levels of ITGB3 are affected. These results further expand our knowledge on the ADAR1-ITGB3 network and its central role in acquisition of the invasive phenotype of metastatic melanoma.
Types de publication
Journal Article
Langues
eng
Pagination
2677-2686Informations de copyright
AJCR Copyright © 2020.
Déclaration de conflit d'intérêts
None.
Références
Biotechnol Lett. 2017 Dec;39(12):1827-1834
pubmed: 28861760
Oncotarget. 2016 Apr 5;7(14):17905-19
pubmed: 26918447
Mol Cell Biol. 2001 May;21(9):3192-205
pubmed: 11287623
Transl Androl Urol. 2020 Apr;9(2):646-653
pubmed: 32420171
Mol Cell Biol. 2005 Aug;25(16):6956-63
pubmed: 16055709
Nat Rev Cancer. 2010 Jan;10(1):9-22
pubmed: 20029421
J Biol Chem. 2008 Aug 29;283(35):23791-800
pubmed: 18579532
Nat Cell Biol. 2015 Mar;17(3):311-21
pubmed: 25686251
Mol Cancer. 2015 Apr 29;14:96
pubmed: 25924850
Oncogene. 2008 Nov 6;27(52):6698-706
pubmed: 18679415
Oncotarget. 2015 Dec 22;6(41):43712-30
pubmed: 26506238
Oncogene. 2010 Jul 22;29(29):4194-204
pubmed: 20498642
Biomed Res Int. 2020 Apr 13;2020:2547902
pubmed: 32351986
J Biol Chem. 2003 Jan 17;278(3):1391-4
pubmed: 12446659
BMC Cancer. 2014 Aug 08;14:577
pubmed: 25106495
RNA. 2004 Aug;10(8):1174-7
pubmed: 15272117
Blood. 1998 Oct 15;92(8):2777-90
pubmed: 9763563
Pigment Cell Melanoma Res. 2013 Jan;26(1):39-57
pubmed: 23095214
Onco Targets Ther. 2015 Sep 22;8:2689-97
pubmed: 26445551
J Mol Biol. 2009 Nov 6;393(4):777-87
pubmed: 19733181
Cancer Lett. 2014 Jan 1;342(1):43-51
pubmed: 23981581
J Cell Biochem. 2018 Nov;119(10):8138-8145
pubmed: 29923255
Genome Biol. 2006;7(4):R27
pubmed: 16594986
Genome Res. 2004 Sep;14(9):1719-25
pubmed: 15342557
Pigment Cell Res. 2007 Jun;20(3):161-72
pubmed: 17516924
Mol Cancer Ther. 2012 Jun;11(6):1300-10
pubmed: 22466331
J Clin Invest. 2013 Jun;123(6):2703-18
pubmed: 23728176
Nat Commun. 2018 May 31;9(1):2154
pubmed: 29855470
Oncol Rep. 2020 Feb;43(2):646-654
pubmed: 31894275
Mol Med Rep. 2018 Aug;18(2):2492-2498
pubmed: 29901141
Cell. 2013 Apr 25;153(3):575-89
pubmed: 23622242
Int J Mol Med. 2017 Jun;39(6):1371-1380
pubmed: 28440426
Cell Physiol Biochem. 2016;39(3):1165-76
pubmed: 27576787
PLoS One. 2011 Apr 25;6(4):e18936
pubmed: 21541354
Mol Biol Rep. 2014;41(4):2521-7
pubmed: 24443232
RNA Biol. 2010 Sep-Oct;7(5):621-7
pubmed: 21037424
Cell. 2005 Jan 14;120(1):15-20
pubmed: 15652477
Pigment Cell Res. 2005 Jun;18(3):150-9
pubmed: 15892711
Wiley Interdiscip Rev Syst Biol Med. 2009 Sep-Oct;1(2):202-209
pubmed: 20835992
Pigment Cell Melanoma Res. 2011 Apr;24(2):282-94
pubmed: 21087420
Cancer Lett. 2014 Dec 1;355(1):159-67
pubmed: 25193465
Iran J Basic Med Sci. 2019 May;22(5):534-540
pubmed: 31217934
J Virol. 2009 Oct;83(19):10119-28
pubmed: 19605474
Oncotarget. 2015 Oct 6;6(30):28999-9015
pubmed: 26338962